4 – 6 April 2019
Grand Millennium Hotel, Auckland, New Zealand
SHD-AP symposium is designed for professionals involved in structural heart disease management. Clinicians, Nurses, Health Policy Advisors, Hospital Management Staff and other allied health professionals.
Specialist in Coronary & Structural Disease Intervention
Specialist in Coronary & Structural Disease Intervention
Specialist in Intensive Care & Cardiac Imaging
Director, Structural Heart & Valve Center
Columbia University Medical Center
New York, USA
Allison Family Distinguished Chair of Cardiovascular Research
Department of Cardiovascular Surgery
Professor of Cardiovascular Surgery, Institute for Academic Medicine
Weill Cornell Medical College
Chief, Division of Cardiac Anesthesia
Director, Cardiac Interventional Anesthesia
Assistant Professor of Anaesthesia, Harvard Medical School
Department of Anesthesiology, Perioperative and Pain Medicine
Brigham and Women’s Hospital
The following programme detail is subject to change at any time, without notice.
Earlybird registration closes 22 February 2019. All prices are in New Zealand dollars and include GST of 15%.
All delegates are required to officially register, and full payment is required in order to attend the symposium. Payment can be made on invoice by selecting the Pay by Direct Credit/ Internet Banking option during the online registration process (account details will be included on your invoice), or by credit card (Visa or Mastercard only). Credit card payments will incur a 3% surcharge, and will show debit as Outshine Ltd.
On submission of your registration a confirmation will be emailed to you, with your tax invoice/receipt attached.
To amend any registration details, or to cancel your registration, please contact the Symposium Managers via email at firstname.lastname@example.org, or phone +64 7 823 1910.
Symposium rates have been secured at The Grand Millennium Hotel, and accommodation can be booked during the online registration process.
SHD-AP Symposium Rate – $245 per room per night, inclusive of GST and based on single, twin or double occupancy.
It is strongly recommended that you register and book your accommodation prior to Friday 22 February 2019. After this date, any remaining rooms will be released and bookings will be subject to availability.
Accommodation cost is delegates’ own, and full payment should be made directly to the hotel on check-out (your credit card details will be requested during registration to secure your booking only). Cancellation of rooms within 30 days of arrival, incurs a cancellation fee of 100% of the full accommodation cost. A “no-show” will also result in a 100% charge to the delegates’ credit card. Please note, any cancellations must be made directly with the Symposium Managers, and not with the hotel.
The Scientific Steering Committee welcomes abstract and case submissions for both oral and electronic poster presentation at the SHD-AP Symposium 2019.
Submissions Close: 10 March 2019
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With the recent acquisition of St. Jude Medical we now offer the most comprehensive set of solutions, including products and technologies in coronary, cardiac rhythm management, electrophysiology, heart failure, structural heart, vascular and endovascular. Our breadth and depth of industry-leading technologies, along with our combined team of experts, bring you end-to end solutions and services. This means better care and a greater variety of contracting options exclusively focused on delivering increased value and efficiencies for our customers. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 74,000 people. Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.
Edwards Lifesciences is a global leader in the science of pericardial tissue heart valves and hemodynamic monitoring. We partner with physicians to produce innovative medical technology solutions designed to help patients live longer, healthier and more productive lives. Our technologies address large and growing patient populations in which there are significant unmet clinical needs, such as structural heart disease and advanced monitoring of the acutely ill. Each of our product areas has a rich history and unique patient focus.
As a global leader in medical technology, services and solutions, Medtronic improves the health and lives of millions of people each year. We believe our deep clinical, therapeutic and economic expertise can help address the complex challenges — such as rising costs, aging populations and the burden of chronic disease — faced by families and healthcare systems today. But no one can do it alone. That’s why we’re committed to partnering in new ways and developing powerful solutions that deliver better patient outcomes.
Let’s take healthcare Further, Together.
Creating a healthier future together. At Philips, we look beyond technology to the experiences of patients, providers and caregivers across the health continuum from healthy living to prevention, diagnosis, treatment, recovery and home care. Our solutions combine clinical breadth and depth of expertise, technology and services, actionable data, consultative new business models and partnerships. Together, with our customers, we take risks and share responsibility – so that we can transform how care is delivered and experienced. It’s a unique perspective empowering us all to create a healthier future.
Copyright © 2019 Structural Heart Disease Asia Pacific Symposium. All Rights Reserved. Initial concept design by Cirakas Consulting